Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Armata Pharmaceuticals (ARMP) and Moderna (MRNA)

Tipranks - Tipranks - Thu Apr 9, 8:36AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Corbus Pharmaceuticals (CRBP), Armata Pharmaceuticals (ARMP) and Moderna (MRNA).

Easter Sale - 70% Off TipRanks

Corbus Pharmaceuticals (CRBP)

LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $38.00. The company’s shares closed last Wednesday at $10.36, close to its 52-week low of $5.49.

According to TipRanks.com, McCammon is a 5-star analyst with an average return of 95.1% and a 46.5% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Monte Rosa Therapeutics, and Janux Therapeutics Inc. ;'>

Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $39.43, representing a 306.1% upside. In a report issued on April 6, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Armata Pharmaceuticals (ARMP)

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Armata Pharmaceuticals, with a price target of $20.00. The company’s shares closed last Tuesday at $11.95.

According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of 38.2% and a 58.6% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and Sionna Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Armata Pharmaceuticals with a $17.50 average price target.

Moderna (MRNA)

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on Moderna. The company’s shares closed last Wednesday at $52.14, close to its 52-week low of $29.25.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 5.0% and a 49.9% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Recursion Pharmaceuticals, and Perspective Therapeutics. ;'>

Currently, the analyst consensus on Moderna is a Hold with an average price target of $38.00.

Read More on CRBP:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).